- Home
- BH vs CSTL Comparison
BH vs CSTL Comparison
Compare BH & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- CSTL
- Stock Information
- Founded
- BH 1934
- CSTL 2007
- Country
- BH United States
- CSTL United States
- Employees
- BH N/A
- CSTL N/A
- Industry
- BH Restaurants
- CSTL Medical Specialities
- Sector
- BH Consumer Discretionary
- CSTL Health Care
- Exchange
- BH Nasdaq
- CSTL Nasdaq
- Market Cap
- BH 712.7M
- CSTL 848.1M
- IPO Year
- BH N/A
- CSTL 2019
- Fundamental
- Price
- BH $264.55
- CSTL $27.72
- Analyst Decision
- BH
- CSTL Strong Buy
- Analyst Count
- BH 0
- CSTL 6
- Target Price
- BH N/A
- CSTL $39.67
- AVG Volume (30 Days)
- BH 15.9K
- CSTL 301.1K
- Earning Date
- BH 11-08-2024
- CSTL 11-04-2024
- Dividend Yield
- BH N/A
- CSTL N/A
- EPS Growth
- BH 158.68
- CSTL N/A
- EPS
- BH 180.85
- CSTL 0.21
- Revenue
- BH $361,664,000.00
- CSTL $311,878,000.00
- Revenue This Year
- BH N/A
- CSTL $51.36
- Revenue Next Year
- BH N/A
- CSTL N/A
- P/E Ratio
- BH $15.95
- CSTL $131.77
- Revenue Growth
- BH N/A
- CSTL 62.43
- 52 Week Low
- BH $145.95
- CSTL $16.97
- 52 Week High
- BH $266.30
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- BH 72.65
- CSTL 39.67
- Support Level
- BH $232.34
- CSTL $26.30
- Resistance Level
- BH $265.73
- CSTL $27.99
- Average True Range (ATR)
- BH 15.05
- CSTL 1.56
- MACD
- BH 1.58
- CSTL -0.21
- Stochastic Oscillator
- BH 96.26
- CSTL 22.54
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations, and Maxim. The majority of revenue is derived from the Restaurant Operations segment. The Restaurant Operations segment includes Steak n Shake and Western Sizzlin Restaurant businesses.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.